Shelley Potts is stepping down from the Board of Directors at MediPharm Labs Corp., effective December 31, 2025, while Michael Bumby will be rejoining the Board on January 1, 2026, bringing financial and governance expertise. Bumby previously served as CFO at VIVO Cannabis Inc., acquired by MediPharm in 2023, and has experience in both the cannabis and pharmaceutical sectors. The Chair of the Board, Chris Taves, thanked Potts for her leadership and welcomed Bumby back, highlighting his valuable financial expertise and prior experience with both VIVO and MediPharm.

MediPharm Labs, established in 2015, specializes in producing pharmaceutical-quality cannabis concentrates and derivative products. In 2021, the company received a Pharmaceutical Drug Establishment License from Health Canada, making it the only North American company with a commercial-scale domestic Good Manufacturing Practices License for natural cannabinoids extraction. The acquisition of VIVO Cannabis Inc. in 2023 expanded MediPharm’s reach to medical markets in Canada, Australia, and Germany. The company operates in compliance with all applicable laws in the countries it serves.

Read more at GlobeNewswire: MediPharm Labs Announces Board of Directors Changes: